Market Overview

UPDATE: Jefferies Upgrades Vanda Pharmaceuticals to Buy on Tasimelteon Catalyst

Related VNDA
A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus
Vanda Gets FDA Approval For Fanapt Marketing Exclusivity
Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)

Jefferies upgraded Vanda Pharmaceuticals (NASDAQ: VNDA) from Hold to Buy and raised the price target from $3.50 to $6.00.

Jefferies commented, "We're finally giving credit for tasimelteon given 1) surprisingly good recent Non24 Ph.3 data w/clinical sleep efficacy which likely improves FDA receptivity, 2) orphan pricing not confounded by ‘depression' efforts, and 3) approaching regulatory catalysts. We still think it's far from a slam dunk, but even conservatively discounted Tasi contribution is likely big upside from current negative EV level."

Vanda Pharmaceuticals closed at $3.95 on Wednesday.

Latest Ratings for VNDA

Mar 2016JMP SecuritiesMaintainsMarket Outperform
Oct 2015Brean CapitalInitiates Coverage onBuy
Mar 2015JefferiesInitiates Coverage onBuy

View More Analyst Ratings for VNDA
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Analyst Ratings


Related Articles (VNDA)

View Comments and Join the Discussion!